Royal Bank Of Canada Immatics N.V. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$9.78 - $13.49 $215 - $296	-22 Reduced 13.02%	147 $1,000
Q1 2024 Nov 05, 2024	BUY	$10.23 - $12.94 $225 - $284	22 Added 14.97%	169 $1,000
Q1 2024 May 15, 2024	SELL	$10.23 - $12.94 $18,424 - $23,304	-1,801 Reduced 91.42%	169 $1,000
Q4 2023 Feb 14, 2024	BUY	$7.36 - $10.89 $12,880 - $19,057	1,750 Added 795.45%	1,970 $20,000
Q3 2023 Nov 14, 2023	SELL	$11.01 - $12.62 $2,058 - $2,359	-187 Reduced 45.95%	220 $2,000
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $2,362 - $5,075	399 Added 4987.5%	407 $4,000
Q1 2023 May 15, 2023	SELL	$6.74 - $9.44 $8,088 - $11,328	-1,200 Reduced 99.34%	8 $0
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $9,627 - $13,849	1,196 Added 9966.67%	1,208 $10,000
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $13 - $52	4 Added 50.0%	12 $0
Q4 2021 Feb 14, 2022	BUY	$10.81 - $14.38 $64 - $86	6 Added 300.0%	8 $0
Q3 2021 Nov 15, 2021	BUY	$11.58 - $15.46 $23 - $30	2 New	2 $0

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $623M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.